The Changing Landscape of Vaccines Webinar

August 20, 2026

Allergists and immunologists are frequently called upon to provide guidance on vaccine safety, interpret evolving immunization schedules, and address patient concerns influenced by online 
misinformation. This webinar will address three overlapping domains: the role of social media in vaccine hesitancy, the complexity of navigating childhood immunization guidance amid evolving recommendations, and the growing evidence supporting adult vaccination—particularly among individuals over 60, including findings related to recombinant zoster vaccines, cognitive health, and broader trends in vaccine safety and efficacy.

Accreditation
Accreditation with Commendation - ACCME The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Allergists, allied health and other allergy practitioners.

Learning Objectives

Upon completion of this activity, learners should be able to:
•    Evaluate current evidence on vaccine safety and updated immunization schedules to ensure accurate clinical decision-making.
•    Identify common sources of vaccine-related misinformation and the ways in which they influence patient concerns.
•    Integrate practical evidence-based vaccine information into routine clinical practice to strengthen their role as trusted sources for patients and the public.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

Advertising, marketing, or communication firms whose clients are ineligible companies
Bio-medical startups that have begun a governmental regulatory approval process
Compounding pharmacies that manufacture proprietary compounds
Device manufacturers or distributors
Diagnostic labs that sell proprietary products
Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
Manufacturers of health-related wearable products
Pharmaceutical companies or distributors
Pharmacy benefit managers
Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated. 

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
08/19/2026
Course expires: 
12/31/2027
Event starts: 
08/20/2026 - 7:00pm CDT
Event ends: 
08/20/2026 - 8:00pm CDT
Add to calendar: 
Rating: 
0

Joel Brooks, DO, MPH, FACAAI 
Joel Brooks is an Assistant Professor of Pediatrics at Columbia University Vagelos College of Physicians and Surgeons, where he serves as the Associate Program Director of their Allergy and Immunology Fellowship Program. He also serves on a number of committees for the American College of Allergy, Asthma, and Immunology and the American Academy of Allergy, Asthma, and Immunology, including their Vaccine Committee.
Disclosures: Nothing to disclose

Nicole Chase, MD, FACAAI
Nicole Chase is a nationally recognized physician, educator, and thought leader in Allergy and Clinical Immunology. She serves as Associate Professor of Medicine at the University of Minnesota and Partner at St. Paul Allergy & Asthma. Dr. Chase's clinical expertise spans anaphylaxis, asthma, chronic urticaria, and eosinophilic gastrointestinal disease, with a particular focus on novel therapeutics and the immunology of atopic disease. Widely respected by her peers, she has been named a Top Doctor in Minneapolis–St. Paul every year since 2015.  
Disclosures: Advisor-ALK, Amgen Aquestive Therapeutics, ARS Pharmaceuticals | Consultant-Aquestive Therapeutics, Arcutis Biotherapeutics | Speaker-Amgen, ARS Pharmaceuticals

Angela Duff Hogan, MD, FACAAI
Angela Duff Hogan is Professor of Pediatrics at Macon and Joan Brock Virginia Health Sciences at Old Dominion University, Eastern Virginia Medical School in Norfolk, VA in the Allergy & Immunology Division at the Children’s Hospital of the King’s Daughters and is a senior partner of Children’s Specialty Group. Dr. Hogan is a fellow of ACAAI, AAAAI, and AAP. She is chair of the ACAAI Asthma Committee, and member of the executive committee of the Section on Allergy and Immunology (SOAI) for the AAP.
Disclosures: Speaker-ARS Pharmaceuticals

David Stukus, MD, FACAAI
David Stukus is the current President-Elect for the American College of Allergy, Asthma and Immunology. He is a Professor of Clinical Pediatrics in the Division of Allergy and Immunology at Nationwide Children’s Hospital, where he serves as the director of the Food Allergy Treatment Center. Dr. Stukus participates in clinical research, quality improvement, patient advocacy, and medical education. An internationally recognized keynote speaker, he has received named lectureships and awards from national and international organizations. 
Disclosures: Consultant-Aquestive Therapeutics, Genentech | Researcher-ARS Pharmaceuticals, DBV Technologies
 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.